Bavarian Nordic has won US Food and Drug Administration (FDA) approval for its chikungunya vaccine Vimkunya, becoming the ...

There are now two vaccines to protect against chikungunya approved for use in the US, with Bavarian Nordic Vimkunya becoming the first cleared for use in adolescents. The Danish biopharma company ...

Vimkunya is now available in the US for the prevention of disease caused by chikungunya virus in individuals 12 years of age ...

Bavarian Nordic recently expanded its global commercial ... “Following the approvals of our chikungunya vaccine in the US and EU last month, we are excited about the opportunity to expand ...

COPENHAGEN, Denmark, February 14, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that the U.S. Food and Drug Administration (FDA) has approved VIMKUNYATM (Chikungunya Vaccine ...

The European Commission (EC) has authorised the marketing of Bavarian Nordic's Vimkunya - the first chikungunya vaccine approved in Europe for individuals as young as 12 years old. Vimkunya is a ...

First chikungunya vaccine approved in Europe for persons as young as 12 years old.On track for launch in key European markets in the first half of 2025. COPENHAGEN, Denmark, February 28, 2025 – ...

Discover why BVNKF's vaccine innovations, growth catalysts, and compelling valuation after a 52% pullback make it a strong ...

Travel Health revenue includes DKK 50-100 million from the sale of chikungunya vaccines ... of 2025 being light. About Bavarian NordicBavarian Nordic is a global vaccine company with a mission ...

Bavarian Nordic (OTCPK:BVNRY) has received FDA approval for its vaccine Vimkunya for the prevention of chikungunya. The virus-like particle, or VLP, vaccine is approved for people aged 12 and older.

Commercial for North America at Bavarian Nordic. “As the first virus-like particle single-dose, pre-filled syringe chikungunya vaccine, Vimkunya provides a crucial new tool to help protect at ...